DK1140018T3 - Polyol/olie-suspensioner til vedvarende frigørelse af proteiner - Google Patents

Polyol/olie-suspensioner til vedvarende frigørelse af proteiner

Info

Publication number
DK1140018T3
DK1140018T3 DK99968164T DK99968164T DK1140018T3 DK 1140018 T3 DK1140018 T3 DK 1140018T3 DK 99968164 T DK99968164 T DK 99968164T DK 99968164 T DK99968164 T DK 99968164T DK 1140018 T3 DK1140018 T3 DK 1140018T3
Authority
DK
Denmark
Prior art keywords
oil suspensions
polyol
sustained release
proteins
active agent
Prior art date
Application number
DK99968164T
Other languages
English (en)
Inventor
Merrill Seymour Goldenberg
Daxian Shan
Alice C Beekman
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/221,181 external-priority patent/US6245740B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1140018T3 publication Critical patent/DK1140018T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
DK99968164T 1998-12-23 1999-12-20 Polyol/olie-suspensioner til vedvarende frigørelse af proteiner DK1140018T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/221,181 US6245740B1 (en) 1998-12-23 1998-12-23 Polyol:oil suspensions for the sustained release of proteins
US44820599A 1999-11-23 1999-11-23
PCT/US1999/030527 WO2000038652A1 (en) 1998-12-23 1999-12-20 Polyol/oil suspensions for the sustained release of proteins

Publications (1)

Publication Number Publication Date
DK1140018T3 true DK1140018T3 (da) 2004-02-02

Family

ID=26915566

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99968164T DK1140018T3 (da) 1998-12-23 1999-12-20 Polyol/olie-suspensioner til vedvarende frigørelse af proteiner

Country Status (16)

Country Link
EP (1) EP1140018B1 (da)
JP (1) JP2002533378A (da)
KR (1) KR100491815B1 (da)
CN (1) CN1158068C (da)
AT (1) ATE251448T1 (da)
AU (1) AU769610B2 (da)
CA (1) CA2355618C (da)
DE (1) DE69911993T2 (da)
DK (1) DK1140018T3 (da)
ES (1) ES2204187T3 (da)
HU (1) HUP0104756A3 (da)
IL (2) IL143706A0 (da)
PT (1) PT1140018E (da)
SI (1) SI1140018T1 (da)
TW (1) TWI221777B (da)
WO (1) WO2000038652A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
JP4361710B2 (ja) 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
KR101434706B1 (ko) * 2007-02-16 2014-08-26 아스카 세이야쿠 가부시키가이샤 미립자 유성 현탁액을 포함하는 의약 조성물
WO2008106571A2 (en) 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103930437A (zh) 2011-03-16 2014-07-16 安姆根有限公司 Nav1.3和Nav1.7的强效及选择性抑制剂
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Apj受容体アゴニストおよびその使用
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
JP6803236B2 (ja) 2014-06-10 2020-12-23 アムジェン インコーポレイテッド アペリンポリペプチド
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002118A1 (en) * 1983-11-21 1985-05-23 Regents Of The University Of Minnesota A buffered polyol-hormone mixture for use in chronic parenteral hormone administration
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
US5114929A (en) * 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions

Also Published As

Publication number Publication date
AU2483800A (en) 2000-07-31
AU769610B2 (en) 2004-01-29
CA2355618C (en) 2007-03-13
IL143706A0 (en) 2002-04-21
SI1140018T1 (en) 2003-12-31
PT1140018E (pt) 2004-02-27
IL143706A (en) 2008-04-13
KR100491815B1 (ko) 2005-05-27
DE69911993D1 (de) 2003-11-13
ATE251448T1 (de) 2003-10-15
WO2000038652A1 (en) 2000-07-06
JP2002533378A (ja) 2002-10-08
HUP0104756A2 (hu) 2002-04-29
CA2355618A1 (en) 2000-07-06
CN1158068C (zh) 2004-07-21
CN1335765A (zh) 2002-02-13
HUP0104756A3 (en) 2006-04-28
DE69911993T2 (de) 2004-05-19
TWI221777B (en) 2004-10-11
KR20010099864A (ko) 2001-11-09
EP1140018B1 (en) 2003-10-08
ES2204187T3 (es) 2004-04-16
EP1140018A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
DK1140018T3 (da) Polyol/olie-suspensioner til vedvarende frigørelse af proteiner
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
ATE309007T1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
NZ527157A (en) Compositions for delivering bisphosphonates
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
EA199900373A2 (ru) Фармацевтические композиции
DK1401501T3 (da) Orale farmaceutiske sammensætninger med modificeret frigivelse af den aktive ingrediens
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
DK0738152T3 (da) Anvendelse af 2-hydroxy-5-phenylazobenzoesyrederivater som kemopræventive og kemoterapeutiske midler mod coloncancer
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
ATE368023T1 (de) Hydroxydiphenyletherverbindungen
DK0975334T3 (da) Biologisk nedbrydelige mikropartikler til langvarig frigivelse af terapeutiske midler
BR9814549A (pt) "composição farmacêutica contendo cloridrato de bupropion e um estabilizador"
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
EA199900642A1 (ru) Твердые смеси на базе сульфонилкарбамидов и вспомогательных агентов
ES2166045T3 (es) Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos.
BR0001661A (pt) Composições pesticidas
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
WO2001037780A8 (en) Urotensin-ii analogs
HRP20000703B1 (en) Stabile compositions levosimendan and alginic acid
SE9902742D0 (sv) New pharmaceutical formultion